Parkinson's Disease

At Julius Clinical we're dedicated to advancing the treatment of Parkinson's Disease through rigorous clinical trials and innovative research.

Specializing in this neurodegenerative condition, we focus on developing novel therapies to enhance patient outcomes and quality of life. Join us as we push the boundaries of neurodegenerative research, striving to bring new hope and effective treatments to those living with Parkinson’s Disease.

Meet our scientific leader for Parkinson's Disease

Prof. dr. Teus van Laar is Professor of Neurology, Advanced treatment of Parkinson’s Disease, at the UMC Groningen. He is an experienced clinical trialist. In addition he is Director of Parkinon’s Disease Platform Northern Netherlands, Board member of the Dutch Parkinson Scientists and Vice-chair of the Scientific Advisory Board of Parkinson NL.

Meet our scientific leader for Parkinson's Disease

Prif. Fabrizio Stocchi is a Full Professor of Neurology and Director of the Parkinson’s Disease and Movement Disorders Research Center at IRCCS San Raffaele Rome and University “La Sapienza.” Prof. Stocchi’s research focuses on neuropharmacology for movement disorders and neurodegenerative diseases, resulting in numerous publications on Parkinson’s disease. He is also the Scientific Advisor for the Institute for Parkinson’s Disease Research in Vicenza and is a member of several prestigious neurological societies.

Scientific networks

How we operate

Brain Clinical is Julius Clinical’s proprietary network for CNS clinical trials. This network, which covers 13 countries, includes highly experienced and devoted researchers who specialize in streamlined and rigorously executed clinical trials for Parkinson’s Disease treatments.

Partnership

Who we work with

We’re proud partner of

We work closely with the Brain Research Center in the Netherlands, which specialises in high-quality clinical trial execution for the indications dementia and Parkinson’s Disease.

Related webinars

Webinars

Cardio-Metabolic and Renal Diseases, Neurological diseases, ALS

26-11-2024

Webinar – Time to event trial designs in ALS: How useful are they?

On NOVEMBER 26th, 2024, we organised the webinar: Time to event trial designs in ALS: How useful are they? During this webinar, our speakers Ruben van Eijk, Lotte Smets, Jordi van Unnik and host Lieza Exalto explored the following topics:A...

Webinars

Neurological diseases, ALS

27-06-2024

Webinar – Clinical consequences of the New MASLD Nomenclature

On the 27th of June, we organized the webinar: 'Clinical Consequences of the New MASLD Nomenclature' with guest speaker Prof. Maja Thiele.During this webinar, our speaker and hosts dived into the following topics:Is the MASLD nomeclature...

Webinars

Neurological diseases

Webinar: Plasma biomarkers for diagnosis and monitoring of neurodegenerative disorders

On October 15, at 16.00 CEST, we presented the webinar:Plasma biomarkers for diagnosis and monitoring of neurodegenerative disordersTopics that are discussed:Plasma biomarkers, such as Amyloid, pTau and NfL. Treatment effect in ne...

More webinars